Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: A meta-analysis

British Journal of Cancer

Volumn 76, Issue 5, 1997, Pages 661-666

  Ferrandina, G ^a   Scambia, G ^a   Bardelli, F ^b   Benedetti Panici, P ^a   Mancuso, S ^a   Messori, A ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b Drug Information Center   (Italy)

Author keywords

Cathepsin D; Meta analysis; Node negative breast tumour

Indexed keywords

CATHEPSIN D;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

EID: 0030748777     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.442     Document Type: Article

References (42)

1. Aaltonen M, Lipponen P, Kosma VM, Aaltomaa S and Syrjanen K (1995) Prognostic value of Cathepsin-D expression in female breast cancer. Anticancer Res 15: 1033-1037
2. 0 breast carcinoma. Am J Surg Pathol 18: 158-166
3. Berg AT and Shinnar S (1994) Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology 44: 601-608
4. Benraad TJ, Geurtsmoespot A, Sala M, Piffanelli A, Ross A and Foekens JA on Behalf of the EORTC Receptor Study Group (1992) Quality control of Cathepsin D measurement by the EORTC receptor study group. Eur J Cancer 28: 72-75
5. Bevilacqua P, Boracchi P and Gasparini G (1994) Prognostic indicators for earlystage breast carcinoma. Part II; value of Cathepsin D expression, detected by immunocytochemistry. A multiparametric study. Int J Oncol 5: 559-565
6. Collins R, Yusul S and Peto R (1985) Overview of randomised trials of diuretics in pregnancy. Br Med J 290: 17-25
7. Copper MR (1991) The role of chemotherapy for node-negative breast cancer. Cancer 67: 1744-1747
8. Domagala W, Striker G, Weber A and Osborne M (1992) Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years. Am J Pathol 141: 1003-1012
9. Eng Tan P, Benz CC, Dollbaum C, Moore II DH, Edgerton SM, Zawa DT and Thor AD (1994) Prognostic value of Cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. Ann Oncol 5: 329-336
10. Fine HA, Dear KBG, Loeffler JS, Black PML and Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2592
11. Garcia D, Derocq D, Pujol P and Rochefort H (1990) Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 5: 1809-1814
12. Gion M, Mione R, Dittadi R, Romanelli M, Pappagallo L, Capitanio G, Friede U, Barbazza R, Visiona A and Dante S (1995) Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary breast cancer. Eur J Cancer 31: 671-677
13. Gregory WM, Richards MA and Malpas JS (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10: 334-340
14. Henry JA, McCarthy AL, Angus B, Westley BR, May FEB, Nicholson S, Cairns J, Harris AL and Horne CHW (1990) Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer 65: 265-271
15. Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Knabbaz N and Kallioniemi OP (1993) Cathepsin D expression detected by immunohistochemistry has independent value in axillary node-negative breast cancer. J Clin Oncol 11: 36-43
16. Janicke F, Schirmt M, Pache E, Ulm K, Harbeck N, Holler H and Graeff H ,(1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208
17. Joensuu H, Toikkanen S and Isola J (1995) Stromal cell Cathepsin D expression and long-term survival in breast cancer. Br J Cancer 71: 155-159
18. Kandalaft PK, Chang KL, Ahn CW, Traweek ST, Mehta P and Battifora H (1993) Prognostic significance of immunohistochemical analysis of cathepsin D in low-stage breast cancer. Cancer 71: 2756-2763
19. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. Am Statist Assor J 53: 457-483
20. Klein S, Simes J and Blackburn GL (1986) Total parenteral nutrition and cancer clinical trials. Cancer 58: 1378-1386
21. Kute TE, Shao ZM, Sugg NK, Long RT, Russel GB and Case D (1992) Cathepsin D as a prognostic indicator for node-negative breast cancer patients using immunoassays and enzymatic assays. Cancer Res 52: 5198-5203
22. Laupacis A, Sackett DL and Roberts RS (1988) An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318: 1728-1733
23. Liotta LA, Stetler-Stevenson WG and Steeg PS (1991) Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest 9: 543-551
24. McGuire WL (1989) Adjuvant therapy of node-negative breast cancer. N Engl J Med 320: 525-527
25. Messori A and Rampazzo R (1993) Meta-analysis of clinical trials based on censored end-points: simplified theory and implementation of the statistical algorithms on a microcomputer. Comput Progr Meth Biomed 40: 261-267
26. Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, D' Albasio G, De Simone G and Martini N (1994) Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 89: 692-698
27. Namer M, Ramaioli A, Fontana X, Etienne MC, Hry M, Jourlait A, Milano G, Frenay M, Francois E and Lapalus F (1991) Prognostic value of total cathepsin D in breast tumors. Breast Cancer Res Treat 19: 85-93
28. Peto R (1987) Why do we need systematic overviews of randomised trials. Stat Med 6: 233-239
29. Pujol P, Maudelonde T, Daures JP, Rouanet P, Brouillet JP, Pujol H and Rochefort H (1993) A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 71: 2006-2012
30. Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SA, Hilsenbeck SH, Chamness GC and Osborne CK (1994) Calhepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in nodenegative breast cancer. J Clin Oncal 12: 467-474
31. Roger P, Montcourrier P, Maudelonde T, Brouillet JP, Pages A, Laffargue F and Rochefort H (1994) Cathepsin D: immunostaining in paraffin embedded breast cancer cells and macrophages correlation with cytosolic assay. Hum Pathol 25: 63-871
32. Romain S, Murucciole X, Varette I, Bressa C, Brandone H and Martin PM (1990) La Cathepsine D: un facteur pronostique independant dans le cancer du sein. Bull Cancer 77: 439-447
33. Seshadri R, Horsfall DJ, Firgaira F, McCaul K, Setlur V, Chalmers AH, Yeo R, Ingram D, Dawkins H, Haknel R, Allen DM, Beard D, Britten-Jones R, Black R, Biswas B, Bridgewater FHG, Burke AM, Butcher CJ and Carrangis H (1994) The relative prognostic significance of total cathepsin D and Her-2/neu oncogene amplification in breast cancer. Int J Cancer 56: 61-65
34. Simes RJ (1987) Confronting publication bias: a cohort design for meta-unalysis. Stat Med 6: 11-29
35. Spyratos F, Brouillet JP, Defrenne A, Hacene K, Rouess J, Maudelonde T, Brunet M, Andrieu C, Desplaces A and Rochefort H (1989) Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancer 2: 1115-1118
36. Stewart LA and Parmar MK (1993) Meta-analysis of the literature or of individual patient data: is there a difference? Lancer 341: 4I8-422
37. Tandon AK, Chamness GC, Chirgwin JM and McGuire WL (1990) Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297-302
38. Thompson SG (1994) Why sources of heterogeneity in meta-analysis should be investigated. Br Med J 309: 1351-1355
39. Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen U, Khalaf S, Paolucci F, Pau B, Rasmussen BB and Rose C (1989) Association between high concentrations of Mr 52.000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49: 6008-6014
40. Vignon F, Capony F, Chambon M, Freiss G, Garcia M and Rochefort H (1986) Autocrine growth stimulation of the MCF-7 breast cancer cells by the estrogenregulatcd 52k protein. Endocrinology 118: 1537-1540
41. Westley BR and Rochefort H (1970) Estradiol-induced proteins in MCF-7 human breast cancer cell line. Biochem Biophys Res Commun 90: 410-416
42. Winstanley JHR, Leinster SJ, Cooke TG, Westley BR, Platt-Higgins AM and Rudland PS (1993) Prognostic significance of calhepsin-D in patients with breast cancer. Br J Cancer 67: 767-772